Currently, the clinical targeted drugs for BC include poly-(ADP)-ribose polymerase (PARP) inhibitors (PARPi), CDK4/6 inhibitors (CDK4/6i), PI3K inhibitors, and AKT inhibitors, but none of these drugs alone is very effective against TNBC. Here, CDK4 is linked to breast cancer.